Osiris Therapeutics, Inc. (NASDAQ:OSIR)

CAPS Rating: 1 out of 5

A stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas.


Player Avatar Aarin7 (93.24) Submitted: 7/31/2008 1:01:02 PM : Underperform Start Price: $16.00 OSIR Score: +74.20

At $16, this stock is over priced. It has a lot of future potential but has very little profits to speak of. Their trials in adult stem research have shown major break troughs but are expensive. This stock should bloom with a more liberal president in office. In the short term, the stock is a $12-13 stock. In the long term, this stock will eventual explode IF they do not use all of their capital before FDA approval.

Member Avatar RRobertsmith (< 20) Submitted: 1/22/2011 12:12:11 PM
Recs: 0

this is very very tempting to short this stock at $7-7.775 range and band trade it...tooo bad the caps system won't let me do that!

Featured Broker Partners